Compare Automatic Data Processing Inc (ADP) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? Automatic Data Processing Inc trades at $267.79 (market cap $107.69B), while Alnylam Pharmaceuticals, Inc. trades at $223.83 (market cap $29.60B). The key difference: Automatic Data Processing Inc is far larger — about 3.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Automatic Data Processing Inc pays a 2.51% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ADP | ALNY | |
|---|---|---|
Market Cap | $107.69B | $29.60B |
Sector | Industrials | Health |
52-Week High | $309.03 | $491.22 |
52-Week Low | $188.79 | $205.48 |
Enterprise Value | $108.73B | $27.56B |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $268.23, down 1.99% over the past day, with a bullish technical signal from moving averages and a consensus analyst price target of $280.50. The company reported strong earnings beats in recent quarters, with Q4 2026 EPS of $2.62 beating expectations, and maintains robust profitability with a net income margin of 20.11%. Recent news highlights dividend declarations and positive earnings momentum, though valuation ratios like a P/E of 24.78 suggest a premium.
The outlook for ADP is supported by consistent earnings growth and solid cash flow, but high valuation multiples and competitive pressures in payroll processing pose risks. Upside potential exists if the company meets Q3 2026 EPS expectations of $2.78, while macroeconomic labor market trends could impact performance. Analyst sentiment is mixed, with 63.89% holding, indicating cautious optimism amid elevated pricing.
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
